Felicitex Therapeutics Inc.
(Note: This is a unit IPO. Felicitex Therapeutics Inc. revised the terms of its unit IPO in an S-1/A filing dated Oct. 31, 2022, by changing the composition of the units. Each unit now consists of one share of common stock and two warrants – each to buy one share of common stock. The Oct. 31, 2022, filing with the SEC shows that the rest of the unit IPO’s terms remain the same: 2.48 million units at $6.25 per unit to raise $15.5 million. Felicitex Therapeutics has applied to the NASDAQ to list its stock under the proposed symbol “FLCT” and the warrants under the proposed symbol “FLCTW” – the S-1/A filing says.)
We are a preclinical oncology drug development company focused on developing therapies targeting dormant and active cancer cells. We have designed and patented small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired resistance mechanisms. Our drug candidates are intended to be effective across a broad range of solid tumors and hematological cancers. We target a high unmet need in large oncology markets, including non-small cell lung cancer, or NSCLC, glioblastoma multiforme, or GBM, ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia, or ALL.
As an oncology drug development company, we are at the forefront of one of the most promising areas – dormant cancers. These cancers are responsible for resistance, metastasis, and recurrence. We are developing treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.
We have created a pipeline of therapeutic compounds focused primarily on oncology indications of high unmet medical need. Our three most advanced product candidates are listed below:
(Note: Felicitex Therapeutics set terms for its IPO – 2.48 million units at $5.25 to $7.25 per unit to raise $15.5 million, in its S-1/A dated Sept. 16, 2022. Felicitex Therapeutics filed its S-1 on Aug. 10, 2022.)
|Address||27 Strathmore Road Natick, MA 01760|
|Phone Number||(919) 213-0025|
|View Prospectus:||Felicitex Therapeutics Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-1.63 mil (last 12 months)|
|Price range||$5.25 - $7.25|
|Est. $ Volume||$15.5 mil|
|Manager / Joint Managers||Aegis Capital Corp.|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|